"10.1371_journal.pone.0107760","plos one","2014-10-23T00:00:00Z","Jiang Wei; Marcus Freytag; Yvonne Schober; Wolfgang A Nockher; Victor F Mautner; Reinhard E Friedrich; Paul W Manley; Lan Kluwe; Andreas Kurtz","Laboratory for Tumor Genetics, Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Institute of Laboratory Medicine and Pathobiochemistry, Philipps University Marburg, Marburg, Germany; Novartis Institute of Biomedical Research, Basel, Switzerland; Berlin Brandenburg Center for Regenerative Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; Seoul National University, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul, Republic of Korea","Conceived and designed the experiments: AK LK PWM VFM. Performed the experiments: JW MF YS WAN REF. Analyzed the data: JW MF LK AK WAN. Contributed reagents/materials/analysis tools: VFM REF WAN YS PWM. Wrote the paper: JW LK MF AK PWM.","The co-author Paul W. Manley is employed by Novartis. Novartis has financed the study, has developed the drug nilotinib (as well as Glivec) and holds the following patents on nilotinib: Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis US 8604045 B2. The authors confirm that this does not alter their adherence to PLOS ONE policies on sharing data and materials.","2014","10","Jiang Wei","JW",9,TRUE,4,5,5,5,TRUE,TRUE,FALSE,0,NA,FALSE
